{
  "symbol": "BIIB",
  "year": 2024,
  "Period": "Q2",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.1646,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.219
  },
  "top_positive": [
    {
      "sent": "Reference is made in particular to forward-looking statements regarding: \u2022 the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments; \u2022 expectations, plans and prospects relating to product approvals, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; \u2022 the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the execution of our strategic and growth initiatives, including the ultimate success of our acquisitions of Reata and HI-Bio and our ability to realize the anticipated benefits from the acquisitions, including future performance of the SKYCLARYS product and further development of the felzartamab product and anticipated synergies; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures, including our Fit for Growth program; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, regulatory filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability, investigations and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed or pipeline products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the current and potential impacts of geopolitical tensions, acts of war and other large-scale crises, including impacts to our operations, sales and the possible disruptions or delay in our plans to conduct clinical trial activities in areas of geopolitical tension, including regions affected by Russia's invasion of Ukraine and the military conflict in the Middle East; \u2022 the direct and indirect impact of global health outbreaks on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, research and development costs, clinical trials and employees; \u2022 our use of information systems and data and the potential impacts of any breakdowns, invasions, corruptions, destructions and/or breaches of such systems or those of our business partners; 3 Table of Contents \u2022 the potential impact of healthcare reform in the U.S., including the IRA, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the gene therapy manufacturing facility in RTP, North Carolina to be operational; \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards.",
      "score": 0.9884
    },
    {
      "sent": "Reference is made in particular to forward-looking statements regarding: \u2022 the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments; \u2022 expectations, plans and prospects relating to product approvals, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; \u2022 the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the execution of our strategic and growth initiatives, including the ultimate success of our acquisitions of Reata and HI-Bio and our ability to realize the anticipated benefits from the acquisitions, including future performance of the SKYCLARYS product and further development of the felzartamab product and anticipated synergies; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures, including our Fit for Growth program; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, regulatory filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability, investigations and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed or pipeline products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the current and potential impacts of geopolitical tensions, acts of war and other large-scale crises, including impacts to our operations, sales and the possible disruptions or delay in our plans to conduct clinical trial activities in areas of geopolitical tension, including regions affected by Russia's invasion of Ukraine and the military conflict in the Middle East; \u2022 the direct and indirect impact of global health outbreaks on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, research and development costs, clinical trials and employees; \u2022 our use of information systems and data and the potential impacts of any breakdowns, invasions, corruptions, destructions and/or breaches of such systems or those of our business partners; 3 Table of Contents \u2022 the potential impact of healthcare reform in the U.S., including the IRA, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the gene therapy manufacturing facility in RTP, North Carolina to be operational; \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards.",
      "score": 0.9884
    },
    {
      "sent": "AND SUBSIDIARIES NOTES\u00a0TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited, continued) For the Three Months Ended June 30, 2023 (In millions) Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax Currency Translation Adjustments Total Balance, March 31, 2023 $ ( 10.0 ) $ ( 20.3 ) $ ( 0.6 ) $ ( 141.1 ) $ ( 172.0 ) Other comprehensive income (loss) before reclassifications ( 5.5 ) 10.2 0.2 ( 3.4 ) 1.5 Amounts reclassified from AOCI 1.0 ( 3.3 ) \u2014 \u2014 ( 2.3 ) Net current period other comprehensive income (loss) ( 4.5 ) 6.9 0.2 ( 3.4 ) ( 0.8 ) Balance, June 30, 2023 $ ( 14.5 ) $ ( 13.4 ) $ ( 0.4 ) $ ( 144.5 ) $ ( 172.8 ) For the Six Months Ended June 30, 2023 (In millions) Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax Currency Translation Adjustments Total Balance, December 31, 2022 $ ( 15.7 ) $ 15.1 $ ( 1.1 ) $ ( 163.2 ) $ ( 164.9 ) Other comprehensive income (loss) before reclassifications ( 0.2 ) ( 10.1 ) 0.7 18.7 9.1 Amounts reclassified from AOCI 1.4 ( 18.4 ) \u2014 \u2014 ( 17.0 ) Net current period other comprehensive income (loss) 1.2 ( 28.5 ) 0.7 18.7 ( 7.9 ) Balance, June 30, 2023 $ ( 14.5 ) $ ( 13.4 ) $ ( 0.4 ) $ ( 144.5 ) $ ( 172.8 ) The following table summarizes the amounts reclassified from AOCI: (In millions) Amounts Reclassified from AOCI Income Statement Location For the Three Months Ended June 30, For the Six Months Ended June 30, 2024 2023 2024 2023 Gains (losses) on securities available for sale $ \u2014 $ ( 1.3 ) $ \u2014 $ ( 1.8 ) Other (income) expense \u2014 0.3 \u2014 0.4 Income tax (benefit) expense Gains (losses) on cash flow hedges 7.6 2.4 10.5 20.0 Revenue ( 4.9 ) 1.4 ( 7.0 ) 0.9 Operating expense ( 0.2 ) ( 0.1 ) ( 0.1 ) ( 0.2 ) Other (income) expense ( 0.3 ) ( 0.4 ) ( 0.5 ) ( 2.3 ) Income tax (benefit) expense Total reclassifications, net of tax $ 2.2 $ 2.3 $ 2.9 $ 17.0 35 Table of Contents BIOGEN INC.",
      "score": 0.9859
    }
  ],
  "top_negative": [
    {
      "sent": "If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business.",
      "score": -0.9042
    },
    {
      "sent": "If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business.",
      "score": -0.9042
    },
    {
      "sent": "If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business.",
      "score": -0.9042
    }
  ],
  "forward_snippets": [
    "Reference is made in particular to forward-looking statements regarding: \u2022 the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments; \u2022 expectations, plans and prospects relating to product approvals, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; \u2022 the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the execution of our strategic and growth initiatives, including the ultimate success of our acquisitions of Reata and HI-Bio and our ability to realize the anticipated benefits from the acquisitions, including future performance of the SKYCLARYS product and further development of the felzartamab product and anticipated synergies; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures, including our Fit for Growth program; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, regulatory filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability, investigations and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed or pipeline products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the current and potential impacts of geopolitical tensions, acts of war and other large-scale crises, including impacts to our operations, sales and the possible disruptions or delay in our plans to conduct clinical trial activities in areas of geopolitical tension, including regions affected by Russia's invasion of Ukraine and the military conflict in the Middle East; \u2022 the direct and indirect impact of global health outbreaks on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, research and development costs, clinical trials and employees; \u2022 our use of information systems and data and the potential impacts of any breakdowns, invasions, corruptions, destructions and/or breaches of such systems or those of our business partners; 3 Table of Contents \u2022 the potential impact of healthcare reform in the U.S., including the IRA, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the gene therapy manufacturing facility in RTP, North Carolina to be operational; \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards.",
    "You should read this report with the understanding that our actual future results, performance, events and circumstances might be materially different from what we expect.",
    "Reference is made in particular to forward-looking statements regarding: \u2022 the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments; \u2022 expectations, plans and prospects relating to product approvals, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; \u2022 the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the execution of our strategic and growth initiatives, including the ultimate success of our acquisitions of Reata and HI-Bio and our ability to realize the anticipated benefits from the acquisitions, including future performance of the SKYCLARYS product and further development of the felzartamab product and anticipated synergies; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures, including our Fit for Growth program; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, regulatory filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability, investigations and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed or pipeline products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the current and potential impacts of geopolitical tensions, acts of war and other large-scale crises, including impacts to our operations, sales and the possible disruptions or delay in our plans to conduct clinical trial activities in areas of geopolitical tension, including regions affected by Russia's invasion of Ukraine and the military conflict in the Middle East; \u2022 the direct and indirect impact of global health outbreaks on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, research and development costs, clinical trials and employees; \u2022 our use of information systems and data and the potential impacts of any breakdowns, invasions, corruptions, destructions and/or breaches of such systems or those of our business partners; 3 Table of Contents \u2022 the potential impact of healthcare reform in the U.S., including the IRA, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the gene therapy manufacturing facility in RTP, North Carolina to be operational; \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards.",
    "You should read this report with the understanding that our actual future results, performance, events and circumstances might be materially different from what we expect.",
    "AI Artificial Intelligence Alkermes Alkermes plc ALS Amyotrophic Lateral Sclerosis aMN Antibody-positive Membranous Nephropathy AOCI Accumulated Other Comprehensive Income (Loss) ASO Antisense Oligonucleotide ASU Accounting Standards Update ATV Antibody Transport Vehicle BLA Biologics License Application Blackstone Blackstone Life Sciences CCPA California Consumer Privacy Act CHMP Committee for Medicinal Products fo\neata and HI-Bio and our ability to realize the anticipated benefits from the acquisitions, including future performance of the SKYCLARYS product and further development of the felzartamab product and anticipated synergies; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures, including our Fit for Growth program; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, regulatory filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability, investigations and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed or pipeline products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the current and potential impacts of geopolitical tensions, acts of war and other large-scale crises, including impacts to our operations, sales and the possible disruptions or delay in our plans to conduct clinical trial activities in areas of geopolitical tension, including regions affected by Russia's invasion of Ukraine and the military conflict in the Middle East; \u2022 the direct and indirect impact of global health outbreaks on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, research and development costs, clinical trials and employees; \u2022 our use of information systems and data and the potential impacts of any breakdowns, invasions, corruptions, destructions and/or breaches of such systems or those of our business partners; 3 Table of Contents \u2022 the potential impact of healthcare reform in the U.S., including the IRA, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the gene therapy manufacturing facility in RTP, North Carolina to be operational; \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards."
  ],
  "curated_text": "Symbol: BIIB. Year: 2024. Period: Q2. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: Reference is made in particular to forward-looking statements regarding: \u2022 the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments; \u2022 expectations, plans and prospects relating to product approvals, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; \u2022 the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the execution of our strategic and growth initiatives, including the ultimate success of our acquisitions of Reata and HI-Bio and our ability to realize the anticipated benefits from the acquisitions, including future performance of the SKYCLARYS product and further development of the felzartamab product and anticipated synergies; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures, including our Fit for Growth program; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, regulatory filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability, investigations and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed or pipeline products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the current and potential impacts of geopolitical tensions, acts of war and other large-scale crises, including impacts to our operations, sales and the possible disruptions or delay in our plans to conduct clinical trial activities in areas of geopolitical tension, including regions affected by Russia's invasion of Ukraine and the military conflict in the Middle East; \u2022 the direct and indirect impact of global health outbreaks on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, research and development costs, clinical trials and employees; \u2022 our use of information systems and data and the potential impacts of any breakdowns, invasions, corruptions, destructions and/or breaches of such systems or those of our business partners; 3 Table of Contents \u2022 the potential impact of healthcare reform in the U.S., including the IRA, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the gene therapy manufacturing facility in RTP, North Carolina to be operational; \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards. Reference is made in particular to forward-looking statements regarding: \u2022 the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments; \u2022 expectations, plans and prospects relating to product approvals, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; \u2022 the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the execution of our strategic and growth initiatives, including the ultimate success of our acquisitions of Reata and HI-Bio and our ability to realize the anticipated benefits from the acquisitions, including future performance of the SKYCLARYS product and further development of the felzartamab product and anticipated synergies; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures, including our Fit for Growth program; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, regulatory filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability, investigations and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed or pipeline products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the current and potential impacts of geopolitical tensions, acts of war and other large-scale crises, including impacts to our operations, sales and the possible disruptions or delay in our plans to conduct clinical trial activities in areas of geopolitical tension, including regions affected by Russia's invasion of Ukraine and the military conflict in the Middle East; \u2022 the direct and indirect impact of global health outbreaks on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, research and development costs, clinical trials and employees; \u2022 our use of information systems and data and the potential impacts of any breakdowns, invasions, corruptions, destructions and/or breaches of such systems or those of our business partners; 3 Table of Contents \u2022 the potential impact of healthcare reform in the U.S., including the IRA, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the gene therapy manufacturing facility in RTP, North Carolina to be operational; \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards. AND SUBSIDIARIES NOTES\u00a0TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited, continued) For the Three Months Ended June 30, 2023 (In millions) Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax Currency Translation Adjustments Total Balance, March 31, 2023 $ ( 10.0 ) $ ( 20.3 ) $ ( 0.6 ) $ ( 141.1 ) $ ( 172.0 ) Other comprehensive income (loss) before reclassifications ( 5.5 ) 10.2 0.2 ( 3.4 ) 1.5 Amounts reclassified from AOCI 1.0 ( 3.3 ) \u2014 \u2014 ( 2.3 ) Net current period other comprehensive income (loss) ( 4.5 ) 6.9 0.2 ( 3.4 ) ( 0.8 ) Balance, June 30, 2023 $ ( 14.5 ) $ ( 13.4 ) $ ( 0.4 ) $ ( 144.5 ) $ ( 172.8 ) For the Six Months Ended June 30, 2023 (In millions) Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax Currency Translation Adjustments Total Balance, December 31, 2022 $ ( 15.7 ) $ 15.1 $ ( 1.1 ) $ ( 163.2 ) $ ( 164.9 ) Other comprehensive income (loss) before reclassifications ( 0.2 ) ( 10.1 ) 0.7 18.7 9.1 Amounts reclassified from AOCI 1.4 ( 18.4 ) \u2014 \u2014 ( 17.0 ) Net current period other comprehensive income (loss) 1.2 ( 28.5 ) 0.7 18.7 ( 7.9 ) Balance, June 30, 2023 $ ( 14.5 ) $ ( 13.4 ) $ ( 0.4 ) $ ( 144.5 ) $ ( 172.8 ) The following table summarizes the amounts reclassified from AOCI: (In millions) Amounts Reclassified from AOCI Income Statement Location For the Three Months Ended June 30, For the Six Months Ended June 30, 2024 2023 2024 2023 Gains (losses) on securities available for sale $ \u2014 $ ( 1.3 ) $ \u2014 $ ( 1.8 ) Other (income) expense \u2014 0.3 \u2014 0.4 Income tax (benefit) expense Gains (losses) on cash flow hedges 7.6 2.4 10.5 20.0 Revenue ( 4.9 ) 1.4 ( 7.0 ) 0.9 Operating expense ( 0.2 ) ( 0.1 ) ( 0.1 ) ( 0.2 ) Other (income) expense ( 0.3 ) ( 0.4 ) ( 0.5 ) ( 2.3 ) Income tax (benefit) expense Total reclassifications, net of tax $ 2.2 $ 2.3 $ 2.9 $ 17.0 35 Table of Contents BIOGEN INC. Top negative sentences: If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Forward-looking snippets: Reference is made in particular to forward-looking statements regarding: \u2022 the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments; \u2022 expectations, plans and prospects relating to product approvals, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; \u2022 the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the execution of our strategic and growth initiatives, including the ultimate success of our acquisitions of Reata and HI-Bio and our ability to realize the anticipated benefits from the acquisitions, including future performance of the SKYCLARYS product and further development of the felzartamab product and anticipated synergies; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures, including our Fit for Growth program; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, regulatory filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability, investigations and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed or pipeline products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the current and potential impacts of geopolitical tensions, acts of war and other large-scale crises, including impacts to our operations, sales and the possible disruptions or delay in our plans to conduct clinical trial activities in areas of geopolitical tension, including regions affected by Russia's invasion of Ukraine and the military conflict in the Middle East; \u2022 the direct and indirect impact of global health outbreaks on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, research and development costs, clinical trials and employees; \u2022 our use of information systems and data and the potential impacts of any breakdowns, invasions, corruptions, destructions and/or breaches of such systems or those of our business partners; 3 Table of Contents \u2022 the potential impact of healthcare reform in the U.S., including the IRA, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the gene therapy manufacturing facility in RTP, North Carolina to be operational; \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards. You should read this report with the understanding that our actual future results, performance, events and circumstances might be materially different from what we expect. Reference is made in particular to forward-looking statements regarding: \u2022 the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments; \u2022 expectations, plans and prospects relating to product approvals, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; \u2022 the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the execution of our strategic and growth initiatives, including the ultimate success of our acquisitions of Reata and HI-Bio and our ability to realize the anticipated benefits from the acquisitions, including future performance of the SKYCLARYS product and further development of the felzartamab product and anticipated synergies; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures, including our Fit for Growth program; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, regulatory filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability, investigations and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed or pipeline products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the current and potential impacts of geopolitical tensions, acts of war and other large-scale crises, including impacts to our operations, sales and the possible disruptions or delay in our plans to conduct clinical trial activities in areas of geopolitical tension, including regions affected by Russia's invasion of Ukraine and the military conflict in the Middle East; \u2022 the direct and indirect impact of global health outbreaks on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, research and development costs, clinical trials and employees; \u2022 our use of information systems and data and the potential impacts of any breakdowns, invasions, corruptions, destructions and/or breaches of such systems or those of our business partners; 3 Table of Contents \u2022 the potential impact of healthcare reform in the U.S., including the IRA, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the gene therapy manufacturing facility in RTP, North Carolina to be operational; \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards. You should read this report with the understanding that our actual future results, performance, events and circumstances might be materially different from what we expect. AI Artificial Intelligence Alkermes Alkermes plc ALS Amyotrophic Lateral Sclerosis aMN Antibody-positive Membranous Nephropathy AOCI Accumulated Other Comprehensive Income (Loss) ASO Antisense Oligonucleotide ASU Accounting Standards Update ATV Antibody Transport Vehicle BLA Biologics License Application Blackstone Blackstone Life Sciences CCPA California Consumer Privacy Act CHMP Committee for Medicinal Products fo\neata and HI-Bio and our ability to realize the anticipated benefits from the acquisitions, including future performance of the SKYCLARYS product and further development of the felzartamab product and anticipated synergies; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures, including our Fit for Growth program; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, regulatory filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability, investigations and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed or pipeline products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the current and potential impacts of geopolitical tensions, acts of war and other large-scale crises, including impacts to our operations, sales and the possible disruptions or delay in our plans to conduct clinical trial activities in areas of geopolitical tension, including regions affected by Russia's invasion of Ukraine and the military conflict in the Middle East; \u2022 the direct and indirect impact of global health outbreaks on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, research and development costs, clinical trials and employees; \u2022 our use of information systems and data and the potential impacts of any breakdowns, invasions, corruptions, destructions and/or breaches of such systems or those of our business partners; 3 Table of Contents \u2022 the potential impact of healthcare reform in the U.S., including the IRA, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the gene therapy manufacturing facility in RTP, North Carolina to be operational; \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards."
}